Anil Potti

TL;DR: It is shown that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways and linked with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogens pathway signatures to guide the use of targeted therapeutics.

TL;DR: This large-scale genomic analysis illustrates that breast cancer arising in young women is a unique biologic entity driven by unifying oncogenic signaling pathways, is characterized by less hormone sensitivity and higher HER-2/EGFR expression, and warrants further study to offer this poor-prognosis group of women better preventative and therapeutic options.

TL;DR: The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.

TL;DR: Using in vitro drug sensitivity data coupled with Affymetrix microarray data, gene expression signatures that predict sensitivity to individual chemotherapeutic drugs are developed that can accurately predict clinical response in individuals treated with these drugs.

TL;DR: A classification scheme for human breast cancer making use of patterns of pathway activity to build on previous subtype characterizations using intrinsic gene expression signatures, to provide a functional interpretation of the gene expression data that can be linked to therapeutic options.